Holen Sie sich die Stockscreener-App
6.36
0.31%
-0.02
Schlusskurs vom Vortag:
$6.38
Offen:
$6.37
24-Stunden-Volumen:
297.95K
Relative Volume:
0.08
Marktkapitalisierung:
$52.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.82M
KGV:
-5.5473
EPS:
-1.1465
Netto-Cashflow:
$-8.00M
1W Leistung:
-2.45%
1M Leistung:
+523.53%
6M Leistung:
+165.00%
1J Leistung:
+167.23%
1-Tages-Spanne:
$6.10
$6.71
1-Wochen-Bereich:
$5.89
$8.74
52-Wochen-Spanne:
$0.72
$8.74
Edesa Biotech Inc Stock (EDSA) Company Profile
Firmenname
Edesa Biotech Inc
Sektor
Branche
Telefon
(905) 475-1234
Adresse
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
6.25 | 53.26M | 0 | -7.82M | -8.00M | -1.1465 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.22 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.63 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.02 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.96 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.43 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Edesa Biotech Inc Aktie (EDSA) Neueste Nachrichten
EDSA SEC FilingsEdesa Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7% - MarketBeat
Best Biotech Stocks To Follow Today – March 7th - Defense World
Edesa Biotech’s Paridiprubart Trial Success Spurs Market Optimism - StocksToTrade
Edesa Biotech Gains Ground with Positive Clinical and Financial News - timothysykes.com
Will Edesa Biotech Inc. stock attract more institutional investorsPortfolio Performance Report & Weekly Return Optimization Plans - Naître et grandir
Best Biotech Stocks To Follow TodayMarch 7th - MarketBeat
Edesa Biotech Surges Following Promising Clinical Data in ARDS Treatment - StocksToTrade
Edesa Biotech Advances on Promising Drug Trial Results - timothysykes.com
Velan Capital Investment Management LP Increases Stake in Edesa Biotech Inc - GuruFocus
Edesa Biotech reports FQ1 net loss of $2.2 million - MSN
Price Action: Will Edesa Biotech Inc announce a stock splitJuly 2025 Earnings & High Yield Equity Trading Tips - baoquankhu1.vn
Edesa Biotech (NASDAQ:EDSA) CEO Pardeep Nijhawan Acquires 10,000 Shares - MarketBeat
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aug Mood: Can Edesa Biotech Inc be the next market leaderWatch List & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
FY2026 EPS Forecast for Edesa Biotech Decreased by Analyst - Defense World
Point72 group (NASDAQ: EDSA) reports 600,000 shares, 7.2% stake - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Velan Capital details Edesa Biotech (NASDAQ: EDSA) 9.99% stake - Stock Titan
Nijhawan group boosts Edesa Biotech (EDSA) stake to 19.99% in 13D/A - Stock Titan
Edesa Biotech (NASDAQ: EDSA) CEO adds 50,571 shares in open-market buys - Stock Titan
[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan
EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality - Research Tree
Edesa Biotech Advances with Promising Phase 3 Outcomes - StocksToTrade
Edesa Biotech’s Paridiprubart Phase 3 Success Drives Optimism - timothysykes.com
Edesa Biotech’s Strategic Advances Boost Stock Outlook - StocksToTrade
Edesa Biotech Surpasses Expectations with Promising Phase 3 Data - timothysykes.com
EDSA Technical Analysis & ETF Price Forecast - Intellectia AI
Why Is Edesa Biotech, Inc. (EDSA) Stock Up Today? - Meyka
Why Did EDSA Stock Rally More Than 70% Today? - Asianet Newsable
Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains on News of Additional Positive Results from Phase 3 Paridiprubart Study - Investorideas.com
Edesa Biotech stock surges on positive Phase 3 trial data By Investing.com - Investing.com Canada
Edesa Biotech stock surges on positive Phase 3 trial data - Investing.com
Edesa Biotech reports mortality reduction in phase 3 trial By Investing.com - Investing.com Australia
Edesa Biotech Reports Positive Phase 3 Paridiprubart Results - TipRanks
Edesa Biotech reports mortality reduction in phase 3 trial - Investing.com
Edesa Biotech reports additional results from phase 3 paridiprubart study - marketscreener.com
Edesa Biotech shows significant 28-day mortality reduction in 278-patient Phase 3 study - TradingView
Mortality-cutting Phase 3 data boost Edesa Biotech (NASDAQ: EDSA) - Stock Titan
Edesa Biotech Reports Additional Results From Phase 3 Paridiprubart Study - TradingView
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study - GlobeNewswire
Update Recap: Can Edesa Biotech Inc expand into new marketsMarket Trend Review & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Will Edesa Biotech Inc. stock benefit from infrastructure spending2025 Earnings Surprises & Accurate Technical Buy Alerts - mfd.ru
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Edesa Biotech, Inc. SEC 10-Q Report - TradingView
Edesa Biotech Reports Fiscal 1st Quarter 2026 Results - Bitget
Edesa Biotech (Nasdaq: EDSA) widens loss as R&D spending climbs - Stock Titan
Edesa Biotech, Inc. Reports Q1 2026 Financial Results and Updates on Clinical Programs for EB06 and Paridiprubart - Quiver Quantitative
Canada's Edesa Biotech Q1 net loss widens - TradingView
Can Edesa Biotech Inc. expand into new markets2025 Technical Patterns & Expert Verified Movement Alerts - mfd.ru
Gains Recap: Does Edesa Biotech Inc have pricing power2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
Finanzdaten der Edesa Biotech Inc-Aktie (EDSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):